NCT07609381 Clinical Information System Impact on Hospitalized Patients With Chronic Disease
| NCT ID | NCT07609381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Diabete Mellitus |
| Study Type | OBSERVATIONAL |
| Enrollment | 124,240 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 124,240 participants in total. It began in 2026-01-01 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a retrospective, observational study using routinely collected information collected by Alberta Health Services. The study will identify patients with chronic disease, defined by one or more of the following conditions; diabetes mellitus, heart failure, coronary artery disease, chronic kidney disease, or chronic lung disease. Adult residents of Alberta with a chronic disease of interest present upon hospital admission and who survive to hospital discharge will be included in the study cohort. The primary outcome will be the composite of hospital readmission or death within 30 days of discharge. Secondary outcomes will include components of the composite, length of stay, patient experiences related to their hospital to home transition of care, and processes of care. Multi-level interrupted time series analysis will be used to compare outcomes before versus after implementation of the Connect Care CIS.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older at the time of hospital admission. * Residents of Alberta eligible to receive acute-care services in AHS facilities. * Hospitalized for any cause during the study period (5 years pre-implementation and 2 years post-implementation of the CIS). * Meet the validated case definition for one or more of the five key NCDs (diabetes mellitus, chronic kidney disease, coronary artery disease, heart failure, or chronic lung disease) based on ICD codes, laboratory measures, or pharmacy records during standardized lookback periods (up to 5 years for diagnoses; up to 1 year for labs/pharmacy). * Have a qualifying date for the NCD(s) that occurs prior to or during the index hospital admission. * Eligible for inclusion in the primary and patient experience outcomes if they survive to hospital discharge. * May enter multiple sub-cohorts if more than one NCD is present. Exclusion Criteria: * Individuals younger than 18 years at the time of hospital admission. * Non-residents of Alberta or individuals not eligible for care within AHS facilities. * Hospitalizations that end in death (excluded from analyses of the primary outcome and patient experience measures). * Patients without evidence of any of the five key NCDs during the lookback period or at the index hospital admission. * Admissions outside the study period or admissions for which necessary administrative, laboratory, or pharmacy data are unavailable.
Contact & Investigator
Matthew T James, MD, PhD
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT07609381 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabete Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07609381 currently recruiting?
Yes, NCT07609381 is actively recruiting participants. Contact the research team at nsshommu@ucalgary.ca for enrollment information.
Where is the NCT07609381 trial being conducted?
This trial is being conducted at Calgary, Canada.
Who is sponsoring the NCT07609381 clinical trial?
NCT07609381 is sponsored by University of Calgary. The principal investigator is Matthew T James, MD, PhD at University of Calgary. The trial plans to enroll 124,240 participants.